Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-08-31
Based on 1098 first isolates · ED · Febrile UTI / pyelonephritis · 2024-09-01 → 2025-08-31
Emergency department
Per-organism detail: ED urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
piperacillin-tazobactam 81 % (78 %–83 %)
Keep for severe or hospital-onset infections.
Not covered: Enterococcus faecalis (10 %), Staphylococcus aureus (3 %), Escherichia coli (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli not for this site
85 %
80 %
n = 87
meropenem MEM
trend · Escherichia coli reserve
85 %
89 %
n = 87
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
81 %
78 %
n = 87
ciprofloxacin CIP
trend · Escherichia coli
78 %
83 %
n = 87
mecillinam MEC
trend · Escherichia coli not for this site
77 %
75 %
n = 87
ceftriaxone CRO
trend · Escherichia coli
76 %
76 %
n = 87
trimethoprim TMP
trend · Escherichia coli not for this site
73 %
71 %
n = 87
72 %
71 %
n = 87
54 %
54 %
n = 87
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
10 %
n = 87
5 %
8 %
n = 87
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
1 %
n = 87

Most likely organisms for this profile

Escherichia coli
57 %
Enterococcus faecalis
10 %
Klebsiella pneumoniae
10 %
Proteus mirabilis
6 %
Pseudomonas aeruginosa
6 %
Klebsiella oxytoca
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.